Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Seroprevalence of binding and neutralizing antibodies against 18 adeno-associated virus types in patients with neuromuscular disorders

27 Sept 2024

Abstract excerpt

High levels of pre-existing antibodies are a major challenge for the application of viral vectors since they can severely limit their efficacy. To identify promising candidates among adeno-associated virus (AAV) based vectors for future gene therapies for the treatment of hereditary neuromuscular disorders (NMDs), we investigated the antibody levels in sera from patients with NMDs against 18 AAV types, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurogenetic and Muscular Disorders Research
Share to Viral Infections and Immunology Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39399494
DOI: 10.3389/fimmu.2024.1450858

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Seroprevalence of binding and neutralizing antibodies against 18 adeno-associated virus types in patients with neuromuscular disordersPMID 39399494Read ↗

Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular DystrophySemantic proximity Read ↗

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsSemantic proximity Read ↗

Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapySemantic proximity Read ↗

Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapiesSemantic proximity Read ↗

Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.Semantic proximity Read ↗

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacsSemantic proximity Read ↗

Worldwide Epidemiology of Neutralizing Antibodies to Adeno‐Associated VirusesSemantic proximity Read ↗

Understanding AAV vector immunogenicity: from particle to patientSemantic proximity Read ↗

Single Amino Acid Modification of Adeno-Associated Virus Capsid Changes Transduction and Humoral Immune ProfilesSemantic proximity Read ↗

Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible SolutionsSemantic proximity Read ↗

Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.Semantic proximity Read ↗

Adeno-Associated Virus Structural Biology as a Tool in Vector DevelopmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.